BELLEVUE, Wash.--(BUSINESS WIRE)--Overlake Medical Center is actively working with cancer patients choosing to participate in a Phase 1 clinical trial of a new investigational product with the potential to dramatically change the landscape of cancer surgery. Blaze Bioscience’s Tumor Paint BLZ-100 intends to provide real-time visualization by fluorescently illuminating cancer cells during surgery, allowing surgeons to increase their precision and achieve better results.
“We are passionate about finding the best treatments for our patients,” said Dr. Kristi Harrington, breast surgeon and medical director of the Overlake Cancer Center.
